

There's Still Time to Invest in CV-19 Vaccine Stocks

In the U.S., life is beginning to return to normal.

In fact, thanks to the vaccines, daily new infections and deaths are down.

Unfortunately, it's still a major problem for other parts of the world. As noted by The Washington Post, "The emergence of more virulent variants of the virus in countries like Brazil and India and the slowness of vaccination efforts in many places outside the West have contributed to deadly new waves. Coronavirus case counts worldwide are already higher in 2021 than they were in 2020. The death toll almost certainly will be."

In addition, the U.S. CDC isn't even sure how long vaccines will protect people.

As they noted, "Although vaccines are effective at keeping you from getting sick, scientists are still learning how well vaccines prevent you from spreading the virus that causes it to others, even if you do not have symptoms. Early data shows that vaccines help keep people with no symptoms from spreading it, but we are learning more as more people get vaccinated. We're also still learning how long vaccines protect people."

That being the case, vaccine stocks could see even more buy interest, such as Ocugen (OCGN), Pfizer (PFE), Moderna (MRNA), and Vir Technology (VIR).

Look at Ocugen for example.

The company is about to submit its emergency use authorization (EUA) application to the US FDA for its virus vaccine. "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for COVAXIN as planned, which is currently in process and which we expect to submit to the FDA in June. We believe that the FDA's new guidance confirms that Ocugen continues to meet all criteria for submission of an EUA."



Or, look at Vir Biotechnology.

Vir Biotechnology just received US FDA emergency use authorization for its CV-19 antibody treatment for mild to moderate cases in people 12 and older.



As quoted in a company press release, George Scangos, Ph.D., chief executive officer of Vir, said: “Our distinctive scientific approach has led to a single monoclonal antibody that, based on an interim analysis, resulted in an 85% reduction in all-cause hospitalizations or death, and has demonstrated, in vitro, that it retains activity against all known variants of concern, including the emerging variant from India.”

“I believe that sotrovimab is a critical new treatment option in the fight against the current pandemic and potentially for future coronavirus outbreaks, as well. At Vir, our aim is not only to deliver a clinically effective therapy for COVID-19, but also to provide effective therapy against SARS-CoV-2 variants and potential pandemics of tomorrow,” he added.